Market Herald logo

Subscribe

Be the first with the news that moves the market

Immuron reported a third-quarter 66 percent increase in sales. Immuron is a Biopharmaceutical company focused on digestive supplements.

Q3 global sales reaped AUD$616,000 compared to 2018’s Q3 Global sales of $371,000. Year-to-date sales at 31 March reached AUD1.7M, a 23 percent increase.

Q3 sales of the company’s product most popular product, Travelan, surged 73 percent in Australia. US sales of Travelan were similar at 60 percent growth.

The company recently began airing an ad spotlight with Chemist Warehouse for Travelan.

Travelan has also been featured in a partnership with US travel medicine network Passport Health.

Immuron CEO Gary Jacob says the company will focus on continuing the expansion of Travelan sales growth.

“[Travelan sales] within existing markets, coupled with our re-entry into Canada puts us in a strong position for continued growth,” he said.

Immuron rose 16.7 percent in the ASX today.

Please see the announcement attached

IMC by the numbers
More From The Market Herald
Hexima (ASX:HXL) - CEO & Managing Director, Michael Aldridge

" Hexima’s (ASX:HXL) shares plummet on inconclusive clinical results for pezadeftide

Hexima's (ASX:HXL) shares have taken a hit today after phase two preliminary results for its pezadeftide…

" dorsaVi (ASX:DVL) extends agreement with QBE Australia

dorsaVi (ASX:DVL) has extended a deal with insurance provider QBE Australia for a further three years.

" New contract sees X2M Connect (ASX:X2M) cover 80pc of households in Okcheon, South Korea

X2M Connect (ASX:X2M) secures a repeat order to deliver water monitoring and control services to households…
Superloop (ASX:SLC) - Managing Director and CEO, Paul Tyler

" Superloop (ASX:SLC) completes Acurus acquisition

Superloop (ASX:SLC) has completed the acquisition of technology services company Acurus.